Investigational strategies in chronic myelogenous leukemia.

[1]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[2]  E. Estey,et al.  Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[4]  J. Melo,et al.  In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. , 2004, Blood.

[5]  R. Kurzrock,et al.  Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. , 2003, Blood.

[6]  T. Tauchi,et al.  BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  H. Vornlocher,et al.  Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). , 2003, Blood.

[8]  M. Andreeff,et al.  Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase , 2003, Cancer.

[9]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. , 2003, Cancer research.

[10]  A Graham Pockley,et al.  Heat shock proteins as regulators of the immune response , 2003, The Lancet.

[11]  J. Issa,et al.  Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.

[12]  M. Goetz,et al.  The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Kantarjian,et al.  Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. , 2003, Leukemia research.

[14]  H. Kantarjian,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-� , 2022 .

[15]  E. Estey,et al.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.

[16]  D. Conrad,et al.  Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. , 2003, Cancer research.

[17]  Hiroki Sato,et al.  TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. , 2003, Blood.

[18]  A. Grañena,et al.  Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Bhalla,et al.  Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. , 2003, Blood.

[20]  N. Rosen,et al.  A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[22]  Alnawaz Rehemtulla,et al.  TRAIL and Anti-Tumor Responses , 2003, Cancer biology & therapy.

[23]  W. R. Bishop,et al.  Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. , 2003, Molecular cancer therapeutics.

[24]  Kuang-Hung Cheng,et al.  Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.

[25]  R. Kurzrock,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and , 2022 .

[26]  H. Kantarjian,et al.  Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis , 2003, Cancer.

[27]  A. Ganser,et al.  Specific inhibition of bcr-abl gene expression by small interfering RNA. , 2003, Blood.

[28]  Asim Khwaja,et al.  The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases* , 2003, The Journal of Biological Chemistry.

[29]  H. Kantarjian,et al.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.

[30]  D. Fabbro,et al.  Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. , 2003, Blood.

[31]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[32]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[33]  J. Barrett.  Allogeneic stem cell transplantation for chronic myeloid leukemia. , 2003, Seminars in hematology.

[34]  H. Kantarjian,et al.  Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. , 2003, Blood.

[35]  H. Kantarjian,et al.  The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. , 2003, Haematologica.

[36]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[37]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[39]  R. Jove,et al.  Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. , 2002, Cancer research.

[40]  B. Barlogie,et al.  Clinical activity of arsenic trioxide for the treatment of multiple myeloma , 2002, Leukemia.

[41]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[42]  Li Cheng,et al.  p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr , 2002, Oncogene.

[43]  R. Kurzrock,et al.  Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. , 2002, Seminars in hematology.

[44]  B. Druker,et al.  In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. , 2002, Experimental hematology.

[45]  J. Issa,et al.  Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[47]  Phillip D Zamore,et al.  Ancient Pathways Programmed by Small RNAs , 2002, Science.

[48]  H. Kantarjian,et al.  In vitro effects of STI 571‐containing drug combinations on the growth of Philadelphia‐positive chronic myelogenous leukemia cells , 2002, Cancer.

[49]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[51]  H. Kantarjian,et al.  Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.

[52]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[53]  H. Kantarjian,et al.  Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. , 2002, Blood.

[54]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[55]  E. Sausville,et al.  Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. , 2002, Blood.

[56]  G. Hannon.  RNA interference : RNA , 2002 .

[57]  J. Jelinek,et al.  TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors , 2002, Leukemia.

[58]  F. Tamanoi,et al.  Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells , 2001, Cellular and Molecular Life Sciences CMLS.

[59]  H. Kantarjian,et al.  Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. , 2001, Blood.

[60]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[62]  A. Harel-Bellan,et al.  Histone acetylation and disease , 2001, Cellular and Molecular Life Sciences CMLS.

[63]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[64]  J. Issa,et al.  Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.

[65]  H. Mano,et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.

[66]  A. Elefanty,et al.  Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. , 2001, Blood.

[67]  A. Murgo.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. , 2001, The oncologist.

[68]  K. Bhalla,et al.  Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. , 2001, Cancer research.

[69]  W. R. Bishop,et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. , 2001, Blood.

[70]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[71]  G. Daley,et al.  Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. , 2001, Blood.

[72]  K. Bhalla,et al.  Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells , 2001, Leukemia.

[73]  B. Calabretta,et al.  Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. , 2000, Blood.

[74]  K. Kolibaba,et al.  Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.

[75]  B. Cheson,et al.  Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  W. R. Bishop,et al.  Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules* , 2000, The Journal of Biological Chemistry.

[77]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[78]  O. Ottmann,et al.  BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. , 2000, Cancer research.

[79]  N. Heisterkamp,et al.  Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. , 2000, Blood.

[80]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  S. Soignet,et al.  Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. , 2000, Blood.

[82]  K. Bhalla,et al.  Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.

[83]  H. Kantarjian,et al.  In vitro effects of STI571-containing drug combinations on growth of Ph-posittve myelogenous leukemia-derived cells , 2000 .

[84]  E. Sausville,et al.  Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  David M. Rothwarf,et al.  The NF-κB Activation Pathway: A Paradigm in Information Transfer from Membrane to Nucleus , 1999, Science's STKE.

[86]  S. Krichevsky,et al.  ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. , 1999, Blood.

[87]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  B. Cheson,et al.  Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. , 1999, Blood.

[89]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[90]  T. Mcguire,et al.  Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[91]  J. Issa,et al.  Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. , 1999, Blood.

[92]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[93]  J. Larghero,et al.  Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. , 1999, Cancer research.

[94]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[95]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  L. Whitesell,et al.  Molecular chaperones: biology and prospects for pharmacological intervention. , 1998, Pharmacological reviews.

[97]  F. Guilhot,et al.  Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. , 1998, Hematology and cell therapy.

[98]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.

[99]  D. Cortez,et al.  A requirement for NF-κB activation in Bcr–Abl-mediated transformation , 1998 .

[100]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[101]  J. D'halluin,et al.  Activation of p65 NF-κB protein by p210BCR – ABL in a myeloid cell line (P210BCR – ABL activates p65 NF-κB) , 1997, Oncogene.

[102]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[103]  C Chastang,et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.

[104]  M. Baccarani,et al.  Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors , 1997, Leukemia.

[105]  R. Jove,et al.  The hsp90-binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase* , 1997, The Journal of Biological Chemistry.

[106]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[107]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[108]  G. Pawelec,et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.

[109]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[110]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[111]  M. Andreeff,et al.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. , 1995, Blood.

[112]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[113]  R. Weinberg,et al.  Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.

[114]  H. Kantarjian,et al.  Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.

[115]  S. Faderl,et al.  Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells , 1995, British journal of haematology.

[116]  Y. Ben-Neriah,et al.  Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[117]  M. Zion.  DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia , 1994 .

[118]  R. Lechler,et al.  Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. , 1994, Leukemia.

[119]  Wei Chen,et al.  T-cell immunity to the joining region of p210BCR-ABL protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[120]  W. Chen.  T cell immunity to the joining region of p210^ protein. , 1992 .

[121]  Wang Xh,et al.  Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia. , 1988 .

[122]  C. Forkner,et al.  ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIA: PRELIMINARY REPORT , 1931 .